UNSPSC 51292107: Maprotiline mesilate or mesylate

This classification denotes an antidepressant agent with the molecular formula C20H23N.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 22P65W41V0. European Medicines Agency schedules maprotiline mesylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03089MIG. Most nations, for tariff and trade purposes, schedule maprotiline mesylate under HS 29214980. As of Q4 2014, MAPROTILINE MESYLATE remains US FDA's Preferred Term for this commodity. SMILES: CNCCCC12CCC(C3C1CCCC3)C4C2CCCC4.CS(=O)(=O)O.

UNSPSC 51292107 Maprotiline mesilate or mesylate is a Commodity code with little relevant recent activity under its nominal scope. The three posted state and local opportunities tagged to this code are not buying maprotiline mesilate specifically. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 to procure naloxone and drug deactivation systems annually (1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries), due July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, with no specific pharmaceutical products named. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities, with proposals due March 26, 2026 and awarded vendors effective July 1, 2026.

The sourced opportunities involve health systems, state pharmacy benefit programs, and multi-state cooperative purchasing in Florida, Texas, and Minnesota, but none target maprotiline mesilate or comparable tricyclic antidepressants by name. The code shows minimal or misclassified recent procurement activity in the state and local market. Firms evaluating pursuit under this code should verify issuing bodies' actual pharmaceutical formularies and product specifications before investing in pre-bid research, as the taxonomy classification does not align with the work currently being solicited.